PMID- 33723166
OWN - NLM
STAT- MEDLINE
DCOM- 20211119
LR  - 20211119
IS  - 1998-4138 (Electronic)
IS  - 1998-4138 (Linking)
VI  - 17
IP  - 1
DP  - 2021 Jan-Mar
TI  - Drug-induced infiltrative lung disease with weekly paclitaxel in breast cancer: 
      Case series.
PG  - 262-265
LID - 10.4103/jcrt.JCRT_1225_16 [doi]
AB  - Drug-induced infiltrative lung disease (DI-ILD) can be caused by chemotherapeutic 
      agents, antibiotics, antiarrhythmic drugs, and immunosuppressive agents. Common 
      chemotherapeutic drugs causing DI-ILD include bleomycin, mitomycin C, bis 
      (2-chloroethyl)-l-nitrosourea, cyclophosphamide, busulfan, and methotrexate. 
      Taxanes and trastuzumab are also associated with lung injury. Estimated incidence 
      of paclitaxel-induced lung injury is 0.73%-12%. Although cases of 
      paclitaxel-induced lung injury have been reported previously, we found only one 
      published case report of fatal lung injury caused by paclitaxel use. We are 
      reporting the largest case series of seven patients who developed 
      paclitaxel-induced lung injury along with review of literature.
FAU - Raghupathi, Renu
AU  - Raghupathi R
AD  - Department of Medical Oncology, Apollo Hospitals Bangalore, Bengaluru, Karnataka, 
      India.
FAU - Patil, Channappa
AU  - Patil C
AD  - Department of Medical Oncology, Apollo Hospitals Bangalore, Bengaluru, Karnataka, 
      India.
FAU - Dhiman, Pravesh
AU  - Dhiman P
AD  - Department of Medical Oncology, Apollo Hospitals Bangalore, Bengaluru, Karnataka, 
      India.
LA  - eng
PT  - Case Reports
PL  - India
TA  - J Cancer Res Ther
JT  - Journal of cancer research and therapeutics
JID - 101249598
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - K16AIQ8CTM (pertuzumab)
RN  - P188ANX8CK (Trastuzumab)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*adverse 
      effects
MH  - Breast Neoplasms/*drug therapy/pathology
MH  - Female
MH  - Humans
MH  - Lung Diseases/chemically induced/immunology/*pathology
MH  - Middle Aged
MH  - Paclitaxel/administration & dosage
MH  - Pneumonia/chemically induced/immunology/*pathology
MH  - Prognosis
MH  - Trastuzumab/administration & dosage
OTO - NOTNLM
OT  - Breast cancer
OT  - case series
OT  - chemotherapy
OT  - drug-induced infiltrative lung disease
OT  - paclitaxel
COIS- None
EDAT- 2021/03/17 06:00
MHDA- 2021/11/20 06:00
CRDT- 2021/03/16 06:19
PHST- 2021/03/16 06:19 [entrez]
PHST- 2021/03/17 06:00 [pubmed]
PHST- 2021/11/20 06:00 [medline]
AID - JCanResTher_2021_17_1_262_257465 [pii]
AID - 10.4103/jcrt.JCRT_1225_16 [doi]
PST - ppublish
SO  - J Cancer Res Ther. 2021 Jan-Mar;17(1):262-265. doi: 10.4103/jcrt.JCRT_1225_16.